Company News: Dyax, Teva and Shire

Share this article:
Dyax received FDA approval for Kalbitor (ecallantide/DX-88) for treating acute attacks of hereditary angioedema (HAE), a rare, genetic disorder. Kalbitor is the first subcutaneous HAE treatment approved in the US, and analysts from Wolters Kluwer inThought forecast revenue of $600 million US, $850 million worldwide by 2016.

Teva and Shire settled a lawsuit over a supply contract for an authorized generic version of Shire's Adderall XR. No consideration was exchanged by the parties, Shire said. Shire has been supplying an authorized copy of the ADHD drug since April. Teva subsequently filed suit claiming Shire was in breach of contract due to supply issues. As the reason for the suit, Shire cited issues surrounding DEA restrictions placed on how much amphetamine it could ship, amphetamine being the product's active ingredient. After the lawsuit, DEA raised the 2009 quota for Shire, allowing it to supply Teva with additional amphetamine.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.